Current Atherosclerosis Reports

, Volume 13, Issue 2, pp 154–161 | Cite as

The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial

  • Thura T. Abd
  • Danny J. Eapen
  • Ambareesh Bajpai
  • Abhinav Goyal
  • Allen Dollar
  • Laurence Sperling


Much controversy surrounds the use of high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular (CV) risk. Although data regarding the association of hs-CRP with CV disease is extensive and consistent, its role in clinical practice remains unclear. The American Heart Association (AHA) recently published a scientific statement regarding criteria for evaluation of novel markers of CV risk. This article provides a comprehensive review of data regarding hs-CRP as a risk marker for CV disease in the context of these AHA criteria. The impact of the JUPITER trial on the utility of hs-CRP as a risk marker is emphasized. The review concludes with an evidence-based statement regarding the current role of hs-CRP in CV risk prediction.


hs-CRP Cardiovascular disease Coronary heart disease Cardiovascular risk prediction Statins 



The authors report no potential conflicts of interest relevant to this article.

Dr. Antonio Gotto, Editor-in-Chief of Current Atherosclerosis Reports, reviewed this article and provided comments and suggestions. He was a member of the JUPITER Steering Committee, for which he received honoraria, and has served as a consultant for AstraZeneca. He has no financial relationship with the manufacturer of the hs-CRP test.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Berk B, Weintraub W, Alexander R. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol. 1990;65(3):168–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Liuzzo G, Biasucci L, Gallimore J, Grillo R, Rebuzzi A, Pepys M, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331(7):417.PubMedCrossRefGoogle Scholar
  3. 3.
    Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21.PubMedGoogle Scholar
  4. 4.
    Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):2129–38.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto Jr AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195. This is the main article of the JUPITER study. It showed the rosuvastatin therapy in those “apparently” healthy population with elevated hs-CRP of >2 mg/L and low LDL (<130 mg/dL) had decreased cardiovascular risk with the use of rosuvastatin.PubMedCrossRefGoogle Scholar
  6. 6.
    Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408.PubMedCrossRefGoogle Scholar
  7. 7.
    • Bajpai A, Goyal A, Sperling L. Should we measure C-reactive protein on Earth or just on JUPITER? Clin Cardiol. 2010;33(4):190–8. This article provides a comprehensive review of the data regarding cardiovascular risk and hs-CRP with an emphasis on the JUPITER trial .It concludes with an evidence-based analysis of the role of hs-CRP in cardiovascular risk assessment.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirschfield G, Pepys M. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96(11):793.PubMedCrossRefGoogle Scholar
  9. 9.
    Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off ed). 1990;25(3):13.Google Scholar
  10. 10.
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448.PubMedCrossRefGoogle Scholar
  11. 11.
    Vigushin D, Pepys M, Hawkins P. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Investig. 1993;91:1351–1.PubMedCrossRefGoogle Scholar
  12. 12.
    De Beer F, Soutar A, Baltz M, Trayner I, Feinstein A, Pepys M. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med. 1982;156(1):230.PubMedCrossRefGoogle Scholar
  13. 13.
    Pepys M, Rowe I, Baltz M. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol. 1985;27:83.PubMedGoogle Scholar
  14. 14.
    Chang M, Binder C, Torzewski M, Witztum J. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99(20):13043.PubMedCrossRefGoogle Scholar
  15. 15.
    Vigo C. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem. 1985;260(6):3418.PubMedGoogle Scholar
  16. 16.
    Volanakis J, Narkates A. Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol Immunol. 1983;20(11):1201–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang Y, Cliff W, Schoefl G, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999;145(2):375–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19(8):521–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Casas J, Shah T, Hingorani A, Danesh J, Pepys M. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264(4):295–314.PubMedCrossRefGoogle Scholar
  20. 20.
    •• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897. This landmark genetic study showed that polymorphisms in the CRP gene are associated with marked increases in CRP levels but with no increase risk of ischemic vascular disease.PubMedCrossRefGoogle Scholar
  21. 21.
    Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387.PubMedCrossRefGoogle Scholar
  22. 22.
    Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med. 2009;151(7):483.PubMedGoogle Scholar
  23. 23.
    Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.PubMedCrossRefGoogle Scholar
  24. 24.
    May M, Lawlor D, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women’s Heart and Health prospective cohort study. Br Med J. 2006;92(10):1396.Google Scholar
  25. 25.
    Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928.PubMedCrossRefGoogle Scholar
  26. 26.
    Cao J, Arnold A, Manolio T, Polak J, Psaty B, Hirsch C, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116(1):32.PubMedCrossRefGoogle Scholar
  27. 27.
    Sattar N, Murray H, McConnachie A, Blauw G, Bollen E, Buckley B, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115(8):981.PubMedCrossRefGoogle Scholar
  28. 28.
    Shlipak M, Fried L, Cushman M, Manolio T, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293(14):1737.PubMedCrossRefGoogle Scholar
  29. 29.
    Wilson PWF, Nam BH, Pencina M, D’Agostino Sr RB, Benjamin EJ, O’Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165(21):2473.PubMedCrossRefGoogle Scholar
  30. 30.
    Rutter M, Meigs J, Sullivan L, Sr D’Agostino R, Wilson P. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110(4):380.PubMedCrossRefGoogle Scholar
  31. 31.
    Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349.PubMedCrossRefGoogle Scholar
  32. 32.
    Janes H, Pepe M, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med. 2008;149(10):751.PubMedGoogle Scholar
  33. 33.
    •• Pencina MJ, D’Agostino Sr RB, Jr D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. This article intoduces the Net Reclassification Index (NRI) as a novel way of measuring the additive effect of a variable to a model in reclassifying individuals to different risk category.PubMedCrossRefGoogle Scholar
  34. 34.
    Hosmer D, Lemesbow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat-Theory Methods. 1980;9(10):1043–69.CrossRefGoogle Scholar
  35. 35.
    Wilson P, Pencina M, Jacques P, Selhub J, Sr D’Agostino R, O’Donnell C. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1(2):92.PubMedCrossRefGoogle Scholar
  36. 36.
    Cook N. Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by MJ Pencina et al., Statistics in Medicine (DOI. Stat Med. 2008;27(2):191–5.Google Scholar
  37. 37.
    Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217–31.PubMedCrossRefGoogle Scholar
  38. 38.
    McMurray J, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120(22):2188.PubMedCrossRefGoogle Scholar
  39. 39.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959.PubMedCrossRefGoogle Scholar
  40. 40.
    Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2(1):41.PubMedCrossRefGoogle Scholar
  41. 41.
    Lee K, Cipriano L, Owens D, Go A, Hlatky M. Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate-and Low-Cardiovascular-Risk Individuals for Statin Therapy. Circulation. 2010;122:1478–87.PubMedCrossRefGoogle Scholar
  42. 42.
    Slejko JF, Page 2nd RL, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin. 2010;26(10):2485–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Mihaylova B, Briggs A, Hlatky M, Armitage J, Parish S, Gray A, et al. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65–72.CrossRefGoogle Scholar
  44. 44.
    Pletcher M, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243.PubMedGoogle Scholar
  45. 45.
    Hayward R, Krumholz H, Zulman D, Timbie J, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2):69.PubMedGoogle Scholar
  46. 46.
    •• Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol. 2009;104(11):1603–5. This articles analyzes the methodology and results of the JUPITER study. It shows significant epidemiologic and methodologic inconsistencies in the JUPITER study that warrant consideration. The article emphasizes that the study population was not a healthy population and that standard medical care was not provided to the population that could have changed the result of the study significantly.PubMedCrossRefGoogle Scholar
  47. 47.
    Gibbons R, Fugh-Berman A, Chan P, Nallamothu B, Hayward R, Jenny-Avital E, et al. Rosuvastatin in patients with elevated C-reactive protein. N Engl J Med. 2009;360(10):1038.PubMedCrossRefGoogle Scholar
  48. 48.
    • Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, Seshasai S, McMurray J, Freeman D, Jukema J. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010. This study is a meta-analysis of the risk of diabetes mellitus with statin therapy. It concludes that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Thura T. Abd
    • 1
    • 4
  • Danny J. Eapen
    • 1
    • 5
  • Ambareesh Bajpai
    • 2
  • Abhinav Goyal
    • 1
    • 3
    • 6
  • Allen Dollar
    • 1
    • 7
  • Laurence Sperling
    • 1
    • 8
  1. 1.Department of Medicine, Division of CardiologyEmory University School of MedicineAtlantaUSA
  2. 2.Piedmont Heart InstituteAtlantaUSA
  3. 3.Department of EpidemiologyEmory Rollins School of Public HealthAtlantaUSA
  4. 4.Department of Medicine, J. Willis Hurst Internal Medicine Residency ProgramEmory University School of MedicineAtlantaUSA
  5. 5.AtlantaUSA
  6. 6.AtlantaUSA
  7. 7.AtlantaUSA
  8. 8.AtlantaUSA

Personalised recommendations